CHORD - CHOlesterol Lowering and Residual Risk in Type 2 Diabetes

Brief description of study

The purpose of this study is to investigate why individuals with type 2 diabetes are at increased risk for heart disease and stroke. In this study, we will investigate risk factors for heart disease and stroke, including platelet (involved in clotting) activity, inflammation, blood vessel wall function, and genetic information (blueprints of your cells). Participants with type 2 diabetes and elevated cholesterol will receive cholesterol lowering medicines (PCSK9 inhibitor plus statin or ezetimibe) which are therapies designed to prevent heart disease. The study will compare their risk factors before and after cholesterol reduction, and also with healthy control patients with elevated cholesterol who do not have diabetes. The control group will also receive the same cholesterol lowering medicines.


Clinical Study Identifier: s19-01964
ClinicalTrials.gov Identifier: NCT04369664
Principal Investigator: Jeffrey S Berger.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.